Crinetics To Present the Next Generation of Endocrinology Innovation At ENDO 2025 With Eight Presentations From its Deep Pipeline

Benzinga · 06/30 20:12

Long-term Efficacy And Safety Data On Palsonifytm (Paltusotine) In Acromegaly To Be Presented, Including Evidence Of Both Biochemical And Symptom Control With A Well-tolerated Safety Profile In Patients Switching Treatments And Those Not Previously Pharmacologically Treated

Atumelnant Phase 2 Trial Results In Congenital Adrenal Hyperplasia (CAH) To Be Featured In Oral Presentation

Data From Early-Stage Development Program In Graves' Hyperthyroidism And Orbitopathy Also To Be Featured